ISDA

Deposition Date 2025-02-11

Release Date 2025-05-28

Last Version Date 2025-05-28

Entry Detail

PDB ID:

9NA4

Keywords:

IMMUNE SYSTEM,TRANSFERASE/INHIBITOR

Title:

IRAK4 in Complex with Compound 18

Biological Source:

Source Organism:

Homo sapiens (Taxon ID: 9606)

Host Organism:

Spodoptera frugiperda

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

2.33 Å

R-Value Free:

0.27

R-Value Work:

0.22

R-Value Observed:

0.22

Space Group:

P 21 21 2

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Molecule:Interleukin-1 receptor-associated kinase 4
Gene (Uniprot):IRAK4
Chain IDs:A, B, C, D
Chain Length:304
Number of Molecules:4
Biological Source:Homo sapiens

UniProt ID:Q9NWZ3 Pfam ID:PF07714

Primary Citation

Discovery of Edecesertib (GS-5718): A Potent, Selective Inhibitor of IRAK4.

Ammann, S.E, Cottell, J.J, Wright, N.E, Warr, M.R, Snyder, C.A, Bacon, E.M, Brizgys, G, Chin, E, Chou, C, Conway, A, Dick, R.A, Ferrao, R.D, Garrison, K.L, Hammond, A, Lansdon, E.B, Link, J.O, Mukherjee, P.K, Murray, B.P, Mwangi, J, Ndukwe, M.S, Park, G.Y, Serone, A.P, Suekawa-Pirrone, K, Yang, Z.Y, Zipfel, S.M, Taylor, J.G, Liebschner, D, Afonine, P.V, Baker, M.L, Bunkoczi, G, Chen, V.B, Croll, T.I, Hintze, B, Hung, L.W, Jain, S, McCoy, A.J, Moriarty, N.W, Oeffner, R.D, Poon, B.K, Prisant, M.G, Read, R.J, Richardson, J.S, Richardson, D.C, Sammito, M.D, Sobolev, O.V, Stockwell, D.H, Terwilliger, T.C, Urzhumtsev, A.G, Videau, L.L, Williams, C.J, Adams, P.D.Show

J.Med.Chem. ? ? ? (2025)

PMID: 40375634 DOI: 10.1021/acs.jmedchem.5c00463

Abstact

Interleukin-1 receptor-associated kinase 4 (IRAK4) activity mediates pro-inflammatory signaling and cytokine production downstream of toll-like and interleukin-1 receptors (TLR, IL-1R). Selective IRAK4 inhibitors have generated interest as potential treatments for inflammatory diseases. Herein, we report the discovery of GS-5718 (edecesertib), a potent, selective, orally bioavailable IRAK4 inhibitor. Key to this endeavor were efforts undertaken to improve the chemical series' profile after a significant hERG liability was encountered for an early compound. GS-5718 was safe and well-tolerated in IND-enabling preclinical animal toxicity studies, demonstrated efficacy in a mouse NZB lupus model, and additionally demonstrated human pharmacokinetic properties suitable for once-daily administration. Edecesertib is currently under clinical evaluation for the treatment of lupus.

Legend

Protein

Chemical

Disease

Primary Citation of related structures